Savolitinib Plus Osimertinib Show a High Response in EGFR-mutated NSCLC Progressed on First-Line Osimertinib Due to MET-driven Resistance Mechanisms By Ogkologos - August 6, 2025 617 0 Facebook Twitter Google+ Pinterest WhatsApp Findings from the SAVANNAH study Source RELATED ARTICLESMORE FROM AUTHOR Giredestrant plus everolimus prolongs PFS among patients with ER-positive, HER2-negative, ESR1-mutated advanced breast cancer after the receipt of a CDK4/6 inhibitor EMA Recommends Granting a Marketing Authorisation for Ensartinib Taking on the RAS Challenge MOST POPULAR FDA Approves Nogapendekin Alfa Inbakicept-pmln for BCG-Unresponsive Non-Muscle Invasive Bladder Cancer April 26, 2024 Trial Tests Abemaciclib As New Option for Early-Stage Breast Cancer January 6, 2021 ¿Qué deben saber las personas con cáncer sobre el consumo de... January 11, 2022 Trialling a new way to boost CAR T-cell therapy June 23, 2021 Load more HOT NEWS Daratumumab Plus Bortezomib and Dexamethasone Regimen Significantly Prolongs OS in Patients... Marine Runs Five Marathons in Five Days to Help Fund Sister’s... Cancer in My Community: Continuing to Improve Australia’s Strong Cancer Survival... Trastuzumab May Improve Survival in Women with Rare Endometrial Cancer
